Lionco Pharmaceutical Group News

Lingkang Pharmaceutical (603669) Investment Value Analysis Report: Low performance has already caused too many businesses to drive new development

Hu tong Securities InternationalDec 16, 2024 10:58

Lingkang Pharmaceutical (603669): cut into the field of CXO and further strengthen the industrial layout

西南證券Dec 18, 2020 00:00

Lingkang Pharmaceutical Industry (603669) coverage report for the first time: "Chemical preparation + API + Medical Service" trinity Lingkang Pharmaceutical Industry seeks New Reform

國盛證券Apr 30, 2020 00:00

Lingkang Pharmaceutical Industry (603669): stable performance and active layout of medical services

西南證券Apr 20, 2020 00:00

Lingkang Pharmaceutical Co., Ltd. (603669): new varieties with high gross profit to consolidate the main force

粵開證券Apr 19, 2020 00:00

Comments on Lingkang Pharmaceutical (603669): the differentiated competition model has the potential to be optimistic about the company's extension expectation.

中信證券Aug 22, 2016 00:00

Lingkang Pharmaceutical (603669): smart Wisdom and focus on Health

中信證券Jul 10, 2015 00:00

Lingkang Pharmaceutical (603669): pricing report on the first day of listing on May 28th

華泰證券May 27, 2015 00:00

[Hengtai Securities] Lingkang Pharmaceutical: the initial pressure position of the company is expected to be 27-33 yuan.

恆泰證券May 20, 2015 00:00

[northeast Securities] Lingkang Pharmaceutical IPO pricing report: excellent Chemical preparation Enterprises

東北證券May 19, 2015 00:00

Lingkang Pharmaceutical (603669): strongly recommended for purchase on May 20

華泰證券May 19, 2015 00:00